Dark Forest Capital Management LP Purchases New Holdings in USANA Health Sciences, Inc. (NYSE:USNA)

Dark Forest Capital Management LP purchased a new position in USANA Health Sciences, Inc. (NYSE:USNA - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 17,245 shares of the company's stock, valued at approximately $619,000. Dark Forest Capital Management LP owned approximately 0.09% of USANA Health Sciences as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Barclays PLC boosted its holdings in shares of USANA Health Sciences by 111.9% in the 3rd quarter. Barclays PLC now owns 27,737 shares of the company's stock worth $1,052,000 after purchasing an additional 14,647 shares during the period. Pzena Investment Management LLC boosted its stake in USANA Health Sciences by 3.6% during the fourth quarter. Pzena Investment Management LLC now owns 1,087,076 shares of the company's stock worth $39,015,000 after buying an additional 37,466 shares during the period. Principal Financial Group Inc. increased its position in USANA Health Sciences by 2.8% during the fourth quarter. Principal Financial Group Inc. now owns 53,603 shares of the company's stock valued at $1,924,000 after acquiring an additional 1,480 shares during the last quarter. Rhumbline Advisers raised its stake in shares of USANA Health Sciences by 39.8% in the fourth quarter. Rhumbline Advisers now owns 49,390 shares of the company's stock valued at $1,773,000 after acquiring an additional 14,068 shares during the period. Finally, Norges Bank purchased a new position in shares of USANA Health Sciences during the 4th quarter worth about $953,000. Institutional investors own 54.25% of the company's stock.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Sidoti lowered USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, February 18th. DA Davidson cut their price objective on USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating on the stock in a research report on Thursday, February 27th. Finally, StockNews.com lowered shares of USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research note on Friday, February 14th.

Insider Activity at USANA Health Sciences

In related news, CEO Jim Brown sold 5,000 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $29.47, for a total transaction of $147,350.00. Following the completion of the transaction, the chief executive officer now directly owns 15,716 shares in the company, valued at $463,150.52. The trade was a 24.14 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider David Mulham Mulham sold 3,234 shares of USANA Health Sciences stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $32.98, for a total value of $106,657.32. Following the transaction, the insider now owns 12,775 shares of the company's stock, valued at $421,319.50. The trade was a 20.20 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 15,920 shares of company stock valued at $500,285 in the last three months. 0.63% of the stock is owned by insiders.

USANA Health Sciences Trading Up 1.1 %

Shares of USNA traded up $0.30 during midday trading on Tuesday, reaching $27.84. 220,213 shares of the stock were exchanged, compared to its average volume of 123,151. The company's 50 day moving average is $27.78 and its two-hundred day moving average is $33.12. The company has a market capitalization of $525.06 million, a P/E ratio of 9.84, a PEG ratio of 0.93 and a beta of 1.00. USANA Health Sciences, Inc. has a 52 week low of $23.10 and a 52 week high of $49.78.

USANA Health Sciences (NYSE:USNA - Get Free Report) last posted its earnings results on Tuesday, April 22nd. The company reported $0.73 EPS for the quarter, beating analysts' consensus estimates of $0.70 by $0.03. The business had revenue of $249.54 million for the quarter, compared to the consensus estimate of $243.08 million. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. During the same quarter last year, the firm posted $0.86 EPS. On average, sell-side analysts expect that USANA Health Sciences, Inc. will post 2.45 EPS for the current year.

USANA Health Sciences Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.